Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains.
We investigated the effects of combining tacrolimus and azole antifungal agents in azole-resistant strains of Candida albicans by comparing the accumulation of [3H]itraconazole. The CDR1-expressing resistant strain C26 accumulated less itraconazole than the CaMDR-expressing resistant strain C40 or the azole-sensitive strain B2630. A CDR1-expressing Saccharomyces cerevisiae mutant, DSY415, showed a marked reduction in the accumulation of both fluconazole and itraconazole. A CaMDR-expressing S. cerevisiae mutant, DSY416, also showed lower accumulation of fluconazole, but not of itraconazole. The addition of sodium azide, an electron-transport chain inhibitor, increased the intracellular accumulation of itraconazole only in the C26 strain, and not in the C40 or B2630 strains. Addition of tacrolimus, an inhibitor of multidrug resistance proteins, resulted in the highest increase in itraconazole accumulation in the C26 strain. The combination of itraconazole and tacrolimus was synergic in azole-resistant C. albicans strains. In the C26 strain, the MIC of itraconazole decreased from >8 to 0.5 mg/L when combined with tacrolimus. Our results showed that two multidrug resistance phenotypes (encoded by the CDR1 and CaMDR genes) in C. albicans have different substrate specificity for azole antifungal agents and that a combination of tacrolimus and azole antifungal agents is effective against azole-resistant strains of C. albicans.
The Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
S
S
Maesaki
P
P
Marichal
M A
MA
Hossain
D
D
Sanglard
H
H
Vanden Bossche
S
S
Kohno
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology; D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000382:microbiology; D004352:Drug Resistance, Microbial / Q000235:genetics; D018432:Drug Resistance, Multiple / Q000235:genetics; D004357:Drug Synergism; D015725:Fluconazole / Q000378:metabolism; D005656:Fungal Proteins / Q000235:genetics; D015966:Gene Expression Regulation, Fungal; D019450:Genes, MDR / Q000235:genetics; D006801:Humans; D017964:Itraconazole / Q000037:antagonists & inhibitors / Q000378:metabolism; D026901:Membrane Transport Proteins; D008826:Microbial Sensitivity Tests; D016559:Tacrolimus / Q000494:pharmacology*
D000935:Antifungal Agents; D001393:Azoles; C094693:CDR1 protein, Candida albicans; D005656:Fungal Proteins; D026901:Membrane Transport Proteins; D017964:Itraconazole; D015725:Fluconazole; D016559:Tacrolimus